Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 402

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 402
---
 and do not plan to develop such capacity in the foreseeable future. Dry-Lab We rely on Amazon Web Services as our primary provider for cloud computing and data storage solutions. In our commitment to safeguarding the confidentiality and integrity of patient data, we adhere to the latest cybersecurity standards, striving to achieve the utmost level of protection. We understand that our practices are substantially compliant with the Health Insurance Portability and Accountability Act, reflecting our dedication to maintaining the security 203 and privacy of patient information. To ensure a robust defense against potential cyber threats, we enforce stringent cybersecurity measures that apply to both our internal employees and our external partners. These precautions are designed to prevent unauthorized access, ensuring that patient data remains secure and confidential across all points of interaction. We also apply internal solutions to patients’ bioinformatic pipelines using open -sourcesoftware. For specific and key tasks, we trust external partners. For example, to produce the final report for Heritas Diagnostics, we utilize GNX Data Systems, Ltd.’s medical genetics platform Franklin to enable more personalized and targeted therapies. Customer Concentration and Revenue Trends We rely on our indirect shareholders and commercial partnerships, such as CIBIC, which provides for a significant part of our revenue and accounted for 97.9%, 93.5% and 96.6% of revenues for the six months ended December31, 2024 and for the years ended June 30, 2024 and 2023, respectively. CIBIC is the exclusive distributor in Argentina for our diagnostic tests. This allows the use of CIBIC’s commercial channels in a business -to -businessmodel, as other CIBIC products complement our product offerings in Argentina. This model does not apply to Rewell, where CIBIC neither distributes the product nor holds exclusivity over it, functioning in a business -to-business-to-consumerdistribution model. As this product grows, dependence on CIBIC will decrease. Additionally, CIBIC will not participate in sales of our Heritas Diagnostic and Rewell products in countries other than Argentina. Other funding sources will include: Rewell in Argentina (business to consumer or business -to -business); Diagnostics and Rewell in other countries. The distribution model reduces the risks associated with product market entry (both commercial and regulatory) in each country and, in parallel, allows exclusive distribution to be anchored to a business plan that the distributor must meet, minimizing the initial risk of operations in each country. In addition, we receive payments from a variety of sources, including patients